CN114732130A - 含雨生红球藻且抑制胃粘膜受损的组合物及其应用 - Google Patents
含雨生红球藻且抑制胃粘膜受损的组合物及其应用 Download PDFInfo
- Publication number
- CN114732130A CN114732130A CN202210362164.3A CN202210362164A CN114732130A CN 114732130 A CN114732130 A CN 114732130A CN 202210362164 A CN202210362164 A CN 202210362164A CN 114732130 A CN114732130 A CN 114732130A
- Authority
- CN
- China
- Prior art keywords
- haematococcus pluvialis
- extract
- composition
- volume ratio
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000168517 Haematococcus lacustris Species 0.000 title claims abstract description 74
- 239000000203 mixture Substances 0.000 title claims abstract description 38
- 210000001156 gastric mucosa Anatomy 0.000 title claims abstract description 24
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 24
- 239000000284 extract Substances 0.000 claims abstract description 32
- 239000000944 linseed oil Substances 0.000 claims abstract description 11
- 235000021388 linseed oil Nutrition 0.000 claims abstract description 11
- 239000009429 Ginkgo biloba extract Substances 0.000 claims abstract description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 42
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 36
- 230000006378 damage Effects 0.000 claims description 27
- 239000000706 filtrate Substances 0.000 claims description 18
- 239000003208 petroleum Substances 0.000 claims description 18
- 238000001914 filtration Methods 0.000 claims description 15
- 230000002496 gastric effect Effects 0.000 claims description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 12
- 235000019441 ethanol Nutrition 0.000 claims description 12
- 239000003960 organic solvent Substances 0.000 claims description 12
- 235000011201 Ginkgo Nutrition 0.000 claims description 10
- 235000008100 Ginkgo biloba Nutrition 0.000 claims description 10
- 239000000243 solution Substances 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 239000003549 soybean oil Substances 0.000 claims description 7
- 235000012424 soybean oil Nutrition 0.000 claims description 7
- 238000009835 boiling Methods 0.000 claims description 6
- 239000012153 distilled water Substances 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 6
- 239000000047 product Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 4
- 238000007605 air drying Methods 0.000 claims description 3
- 238000004140 cleaning Methods 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 238000005520 cutting process Methods 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 238000002386 leaching Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000011259 mixed solution Substances 0.000 claims description 3
- 230000007935 neutral effect Effects 0.000 claims description 3
- 239000003921 oil Substances 0.000 claims description 3
- 235000019198 oils Nutrition 0.000 claims description 3
- 239000002244 precipitate Substances 0.000 claims description 3
- 210000000582 semen Anatomy 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 241000218628 Ginkgo Species 0.000 claims 3
- 230000000694 effects Effects 0.000 abstract description 5
- 239000000419 plant extract Substances 0.000 abstract description 4
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 20
- 235000013793 astaxanthin Nutrition 0.000 description 20
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 20
- 239000001168 astaxanthin Substances 0.000 description 20
- 229940022405 astaxanthin Drugs 0.000 description 20
- 230000000052 comparative effect Effects 0.000 description 13
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 12
- 244000194101 Ginkgo biloba Species 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 229960000905 indomethacin Drugs 0.000 description 6
- 208000014674 injury Diseases 0.000 description 6
- 230000003078 antioxidant effect Effects 0.000 description 5
- 208000007882 Gastritis Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 4
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 229960002986 dinoprostone Drugs 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 235000021466 carotenoid Nutrition 0.000 description 2
- 150000001747 carotenoids Chemical class 0.000 description 2
- 208000023652 chronic gastritis Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 201000005917 gastric ulcer Diseases 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 244000061520 Angelica archangelica Species 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000195627 Chlamydomonadales Species 0.000 description 1
- 241000196319 Chlorophyceae Species 0.000 description 1
- 241000037740 Coptis chinensis Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 235000001287 Guettarda speciosa Nutrition 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 244000116484 Inula helenium Species 0.000 description 1
- 235000002598 Inula helenium Nutrition 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 229940068052 ginkgo biloba extract Drugs 0.000 description 1
- 235000020686 ginkgo biloba extract Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002656 inhibitory effect on ulcer Effects 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000003244 pro-oxidative effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/55—Linaceae (Flax family), e.g. Linum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Food Science & Technology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Nutrition Science (AREA)
- Microbiology (AREA)
- Polymers & Plastics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及含雨生红球藻且抑制胃粘膜受损的组合物及其应用,属于保健品领域,本发明按照重量份计包括以下成分:雨生红球藻初次提取物40‑60份、雨生红球藻二次提取物60‑80份、银杏叶提取物50‑70份、亚麻籽油300‑500份;本发明雨生红球藻初次提取物、雨生红球藻二次提取物、银杏叶提取物这三种植物提取物的组合物有抑制胃粘膜受损的作用,亚麻籽油的添加对这三种植物提取物的组合物有明显的协同增效的作用。本发明能起到抑制胃粘膜受损的作用。
Description
技术领域
本发明属于保健品领域,具体的说,涉及一种含雨生红球藻且抑制胃粘膜受损的组合物及其应用。
背景技术
胃黏膜损伤可能会导致人民出现呕吐、黑便、腹胀腹痛、食欲不振等症状,对人们的日常生活造成不良影响。此外,胃黏膜损伤是导致胃溃疡及急慢性胃炎的主要病理生理学环节。目前,在抑制胃粘膜受损的中药组合物中,大多使用黄芪、当归、厚朴、黄连、木香、干姜等传统中药组成,其制备方法较为简单,无法提取到有效成分。
雨生红球藻隶属于绿藻纲Chlorophyceae、团藻目Volvocales,是一种广泛分布于自然界中的单细胞淡水绿藻,在高光、氮缺失等胁迫条件下可以大量积累虾青素。虾青素具有强大的抗氧化能力,但不具备其他类胡萝素所具有的典型的助氧化作用。另外,虾青素不是维生素的前体,过量摄入也不会使生物体遭受维生素过多症的威胁。因此,基于虾青素的安全性及其对人类和动物健康的有益效果,已经成为最重要的类胡萝卜素生产对象之一,并被广泛应用于食品保健中。
此外,目前雨生红球藻的研究主要集中在虾青素的高效生产,提取完虾青素后的藻渣作为动物饲料或直接丢弃,雨生红球藻资源未得到充分利用。
因此,进一步开发富含虾青素,且能够安全、有效抑制胃粘膜受损的组合物是十分必要的。
发明内容
为了克服背景技术中存在的问题,本发明提供了一种含雨生红球藻且抑制胃粘膜受损的组合物及其应用,抑制胃粘膜受损,减少胃溃疡及急慢性胃炎的发生。
为实现上述目的,本发明是通过如下技术方案实现的:所述的含雨生红球藻且抑制胃粘膜受损的组合物按照重量份计包括以下成分:雨生红球藻初次提取物40-60份、雨生红球藻二次提取物60-80份、银杏叶提取物50-70份、亚麻籽油300-500份。
进一步的,所述的雨生红球藻初次提取物按照以下步骤制备得到:(1)取干燥雨生红球藻与浓度为4mol/L的盐酸溶液混合,雨生红球藻与盐酸溶液的质量体积比为1:20,在60-80℃下搅拌破壁20-50min,调pH至中性,过滤去掉滤液,留滤渣;(2)将滤渣与浓度为80%的乙醇混合,滤渣与乙醇的质量体积比为1:20,在10-30℃搅拌脱水30min,过滤去掉滤液,得破壁雨生红球藻;(3)将破壁雨生红球藻与有机溶剂混合,破壁雨生红球藻与有机溶剂的质量体积比为1:10,搅拌30min,过滤,滤液浓缩,回收溶剂,得虾青素提取物,收集经过初次提取的雨生红球藻渣。
更进一步的,所述的有机溶剂为乙醇、丙酮、食用大豆油的混合液,有机溶剂中三者体积比为:乙醇:丙酮:食用大豆油=1:2:3;乙醇溶液浓度为80%。
进一步的,所述的雨生红球藻二次提取物按照以下方法制备得到:将经过初次提取的雨生红球藻渣进行干燥,加入蒸馏水,破壁雨生红球藻渣与蒸馏水的质量体积比为1:50,在超声功率,500W条件下提取30min,然后置于80℃的恒温水浴浸提2h,冷却,4000r/min离心10min,取上清液浓缩,加入浓缩后的上清液3倍体积的无水乙醇,静置过夜,再经4000r/min离心10min后取沉淀,用无水乙醇洗涤,冷冻干燥得雨生红球藻二次提取物。
进一步的,所述的银杏叶提取物通过以下方法制备:将银杏叶清洗,晾干,剪碎,加入沸点为60-90℃的石油醚,银杏叶与石油醚质量体积比为1:5,90℃加热回流提取8h,过滤,滤液备用,取滤渣;再加入沸点为60-90℃的石油醚,滤渣与石油醚质量体积比为1:3,90℃加热回流提取3h,过滤,滤液合并,渣弃掉;滤液用单效浓缩器回收石油醚,得石油醚萃取的银杏叶提取物。
进一步的,所述的亚麻籽油制备方法为:将亚麻籽去壳,榨油,既得亚麻籽油。
所述的一种含雨生红球藻且抑制胃粘膜受损的组合物在制备用于抑制抑制胃粘膜受损的产品中的应用。
本发明的有益效果:
本发明包括雨生红球藻初次提取物、雨生红球藻二次提取物、银杏叶提取物、亚麻籽油。其中雨生红球藻初次提取物为虾青素,在虾青素分子中,有很长的共轭双键,有羟基和在共轭双键链末端的不饱和酮,其中羟基和酮基又构成α-羟基酮。虾青素的结构特点使其极易与自由基反应而清除自由基,起到抗氧化作用。虾青素的抗氧化性比β-胡萝卜素高了10倍以上,同时它还比维生素E的抑制脂质过氧化反应特性高100倍以上,被誉为“超级抗氧化剂”,可显著提高人体的免疫力,具有显著的抗疲劳和抗衰老作用,天然虾青素的稳定性、抗氧化活性、生物利用安全性及生物效价等性能均显著优于人工合成产品。虾青素通过抗氧化作用能保护胃黏膜免受损伤,对溃疡形成有抑制作用。
本发明中的雨生红球藻二次提取物为雨生红球藻多糖,雨生红球藻二次提取物可以通过本发明中经过初次提取的雨生红球藻渣制得,也可以通过其他途径提取过虾青素的雨生红球藻渣制得,其他途径包括但不限于:匀浆破壁提取法、超声波破壁提取法、低温研磨法等。雨生红球藻多糖中含有多种多糖组分,具有较好的免疫活性。
银杏叶提取物(GBE)含有黄酮类、内酯类、酚类、萜类、多糖等多种活性物质,具有抗氧化、抑菌、提高免疫、抗炎、抗病毒、降血糖、降血脂、抗肿瘤和抗癌等多种生物活性。亚麻籽油中含有较高含量的α-亚麻酸含量,α-亚麻酸是人体必需脂肪酸。
雨生红球藻初次提取物、雨生红球藻二次提取物、银杏叶提取物这三种植物提取物的组合物有抑制胃粘膜受损的作用,亚麻籽油的添加对这三种植物提取物的组合物有明显的协同增效的作用。
本发明使用雨生红球藻初次提取物、雨生红球藻二次提取物、银杏叶提取物以及亚麻籽油制备产品,能起到抑制胃粘膜受损的作用。
具体实施方式
为了使本发明的目的、技术方案和有益效果更加清楚,下面将对本发明的优选实施例进行详细的说明,以方便技术人员理解。
实施例1-3的组合物组份及重量份数如表1所示。
表1实施例1-3组合物组份及重量份数
对比例1-4的组合物组份及重量份数如表2所示。
表2对比例1-4的组合物组份及重量份数
按照下列方法制备实施例1-3组合物、对比例1-4组合物中的各个组分。
雨生红球藻初次提取物按照以下步骤制备得到:(1)取干燥雨生红球藻与浓度为4mol/L的盐酸溶液混合,雨生红球藻与盐酸溶液的质量体积比为1:20,在60-80℃下搅拌破壁20-50min,调pH至中性,过滤去掉滤液,留滤渣;(2)将滤渣与浓度为80%的乙醇混合,滤渣与乙醇的质量体积比为1:20,在10-30℃搅拌脱水30min,过滤去掉滤液,得破壁雨生红球藻;(3)将破壁雨生红球藻与有机溶剂混合,破壁雨生红球藻与有机溶剂的质量体积比为1:10,搅拌30min,过滤,滤液浓缩,回收溶剂,得虾青素提取物,收集经过初次提取的雨生红球藻渣。有机溶剂为乙醇、丙酮、食用大豆油的混合液,有机溶剂中三者体积比为:乙醇:丙酮:食用大豆油=1:2:3;乙醇溶液浓度为80%。
雨生红球藻二次提取物按照以下方法制备得到:将经过初次提取的雨生红球藻渣进行干燥,加入蒸馏水,破壁雨生红球藻渣与蒸馏水的质量体积比为1:50,在超声功率,500W条件下提取30min,然后置于80℃的恒温水浴浸提2h,冷却,4000r/min离心10min,取上清液浓缩,加入浓缩后的上清液3倍体积的无水乙醇,静置过夜,再经4000r/min离心10min后取沉淀,用无水乙醇洗涤,冷冻干燥得雨生红球藻二次提取物。
银杏叶提取物通过以下方法制备:将银杏叶清洗,晾干,剪碎,加入沸点为60-90℃的石油醚,银杏叶与石油醚质量体积比为1:5,90℃加热回流提取8h,过滤,滤液备用,取滤渣;再加入沸点为60-90℃的石油醚,滤渣与石油醚质量体积比为1:3,90℃加热回流提取3h,过滤,滤液合并,渣弃掉;滤液用单效浓缩器回收石油醚,得石油醚萃取的银杏叶提取物。
亚麻籽油制备方法为:将亚麻籽去壳,榨油,既得亚麻籽油。
效果验证部分
实施例与对比例对胃黏膜***素E2(PGE2)含量的影响
胃黏膜上皮细胞不断地合成和释放内源性PGE2,PGE2具有防止各种有害物质对消化道上皮细胞损伤和致坏死作用。
一、试剂与药品
吲哚美辛购自安徽酷尔生物工程有限公司。
二、实验方法
雄性昆明种小鼠18-22g,购自北京维通利华实验动物技术有限公司。
小鼠随机分为9组每组8只,包括空白对照组、造模对照组,实施例1-3组,对比例1-4组,实验前空白对照组、造模对照组给予生理盐水灌胃,每日2次,每次0.2ml,共5d;实施例1-3组,对比例1-4组分别给予实施例1-3、对比例1-4所制得的组合物,每日2次,每次0.2ml,共5d。实验前禁食24h自由饮水。
三、造模
吲哚美辛诱发的胃损伤模型:在最后一次给予生理盐水、实施例1-3组合物、对比例1-3组合物灌胃后1h每只小鼠肌肉注射吲哚美辛(40mg/kg)0.2ml,5h后处死小鼠,空白对照组注射生理盐水,剂量为0.2ml。
四、胃黏膜损伤评价
将小鼠胃固定于10%甲醛溶液中20min后沿大弯剪开冲洗,放置于显微镜下观察,借助测微尺(精确度0.011mm)计数损伤面积。胃粘膜损伤程度用损伤指数表示。粘膜条索状损伤的长度大于1mm者测量其长度,每毫米计1分,若其宽度大于1mm者,将其计分加倍;若其长度与宽度均小于1mm者,计0.5分。将计分相加即为该只动物损伤指数
PGE2含量采用紫外分光光度法进行测定。
五、结果
组别 | 胃损伤指数 | PGE<sub>2</sub>含量 |
空白对照组 | 0 | 0.331±0.041 |
造模对照组 | 100±10.31 | 0.076±0.024 |
实施例1 | 40.89±9.24 | 0.320±0.045 |
实施例2 | 42.71±9.61 | 0.317±0.031 |
实施例3 | 42.31±8.33 | 0.327±0.034 |
对比例1 | 75.62±8.64 | 0.176±0.037 |
对比例2 | 76.31±9.12 | 0.197±0.026 |
对比例3 | 75.48±8.66 | 0.192±0.032 |
对比例4 | 76.03±9.04 | 0.190±0.024 |
从以上数据可以看出,使用实施例1-3的组合物预防性给药,胃损伤指数显著低于造模对照组和对比例1-4组。
本实验采用吲哚美辛诱发的模型发现小鼠肌肉注射吲哚美辛后5h胃黏膜出现明显糜烂、出血和坏死脱落,并且胃黏膜中PGE2含量明显减少而使用实施例1-3的组合物预防性给药可明显改善胃黏膜损伤状况,同时显著提高肌肉注射吲哚美辛后,小鼠胃黏膜中降低的PGE2水平,本发明可以抑制胃粘膜的损伤。
最后说明的是,以上优选实施例仅用于说明本发明的技术方案而非限制,尽管通过上述优选实施例已经对本发明进行了详细的描述,但本领域技术人员应当理解,可以在形式上和细节上对其作出各种各样的改变,而不偏离本发明权利要求书所限定的范围。
Claims (7)
1.含雨生红球藻且抑制胃粘膜受损的组合物,其特征在于:所述的组合物按照重量份计包括以下成分:雨生红球藻初次提取物40-60份、雨生红球藻二次提取物60-80份、银杏叶提取物50-70份、亚麻籽油300-500份。
2.根据权利要求1所述的一种含雨生红球藻且抑制胃粘膜受损的组合物,其特征在于:所述的雨生红球藻初次提取物按照以下步骤制备得到:(1)取干燥雨生红球藻与浓度为4mol/L的盐酸溶液混合,雨生红球藻与盐酸溶液的质量体积比为1:20,在60-80℃下搅拌破壁20-50min,调pH至中性,过滤去掉滤液,留滤渣;(2)将滤渣与浓度为80%的乙醇混合,滤渣与乙醇的质量体积比为1:20,在10-30℃搅拌脱水30min,过滤去掉滤液,得破壁雨生红球藻;(3)将破壁雨生红球藻与有机溶剂混合,破壁雨生红球藻与有机溶剂的质量体积比为1:10,搅拌30min,过滤,滤液浓缩,回收溶剂,得雨生红球藻初次提取物,收集经过初次提取的雨生红球藻渣。
3.根据权利要求2所述的一种含雨生红球藻且抑制胃粘膜受损的组合物,其特征在于:所述的有机溶剂为乙醇、丙酮、食用大豆油的混合液,有机溶剂中三者体积比为:乙醇:丙酮:食用大豆油=1:2:3;乙醇溶液浓度为80%。
4.根据权利要求1所述的一种含雨生红球藻且抑制胃粘膜受损的组合物,其特征在于:所述的雨生红球藻二次提取物按照以下方法制备得到:将经过初次提取的雨生红球藻渣进行干燥,加入蒸馏水,破壁雨生红球藻渣与蒸馏水的质量体积比为1:50,在超声功率,500W条件下提取30min,然后置于80℃的恒温水浴浸提2h,冷却,4000r/min离心10min,取上清液浓缩,加入浓缩后的上清液3倍体积的无水乙醇,静置过夜,再经4000r/min离心10min后取沉淀,用无水乙醇洗涤,冷冻干燥得雨生红球藻二次提取物。
5.根据权利要求1所述的一种含雨生红球藻且抑制胃粘膜受损的组合物,其特征在于:所述的银杏叶提取物通过以下方法制备:将银杏叶清洗,晾干,剪碎,加入沸点为60-90℃的石油醚,银杏叶与石油醚质量体积比为1:5,90℃加热回流提取8h,过滤,滤液备用,取滤渣;再加入沸点为60-90℃的石油醚,滤渣与石油醚质量体积比为1:3,90℃加热回流提取3h,过滤,滤液合并,渣弃掉;滤液用单效浓缩器回收石油醚,得石油醚萃取的银杏叶提取物。
6.根据权利要求1所述的一种含雨生红球藻且抑制胃粘膜受损的组合物,其特征在于:所述的亚麻籽油制备方法为:将亚麻籽去壳,榨油,既得亚麻籽油。
7.根据权利要求1-6任一项所述的一种含雨生红球藻且抑制胃粘膜受损的组合物在制备用于抑制抑制胃粘膜受损的产品中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210362164.3A CN114732130B (zh) | 2022-04-07 | 2022-04-07 | 含雨生红球藻且抑制胃粘膜受损的组合物及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210362164.3A CN114732130B (zh) | 2022-04-07 | 2022-04-07 | 含雨生红球藻且抑制胃粘膜受损的组合物及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114732130A true CN114732130A (zh) | 2022-07-12 |
CN114732130B CN114732130B (zh) | 2024-01-23 |
Family
ID=82278717
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210362164.3A Active CN114732130B (zh) | 2022-04-07 | 2022-04-07 | 含雨生红球藻且抑制胃粘膜受损的组合物及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114732130B (zh) |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2768335A1 (fr) * | 1997-09-12 | 1999-03-19 | Sederma Sa | Compositions a usage cosmetique ou dermopharmaceutique contenant une association d'extrait d'algue et d'exopolysaccharide |
CN1248912A (zh) * | 1997-02-27 | 2000-03-29 | 阿斯塔卡罗坦尼有限公司 | 用于预防和治疗螺杆菌属感染的口服制剂 |
CN103232375A (zh) * | 2013-04-03 | 2013-08-07 | 大连医诺生物有限公司 | 雨生红球藻中虾青素的高效提取新工艺 |
KR20140125506A (ko) * | 2013-04-19 | 2014-10-29 | 한국에너지기술연구원 | 헤마토코커스 플루비알리스로부터 아스타잔틴과 지질의 동시 생산방법 |
CN107173807A (zh) * | 2017-06-13 | 2017-09-19 | 烟台燕园科玛健康产业有限公司 | 一种含藻类提取物的抗氧化保健营养组合物 |
DE202018105422U1 (de) * | 2018-06-21 | 2018-10-19 | U.S. Nutraceuticals, Llc D/B/A Valensa International | Zusammensetzung zur Linderung von Gelenkschmerzen unter Verwendung von Hyaluronsäure und Eierschalenmembrankomponenten |
KR20180118951A (ko) * | 2017-04-24 | 2018-11-01 | 주식회사 메디비젼 | 안구 질환 예방 또는 개선용 건강기능식품 조성물 |
CN110115374A (zh) * | 2019-05-06 | 2019-08-13 | 云南爱尔康生物技术有限公司 | 一种增强免疫的雨生红球藻褐藻多糖精片及其制备方法 |
US20200289433A1 (en) * | 2019-03-14 | 2020-09-17 | Bioptik Technology, Inc. | Astaxanthin compound composition and the method thereof |
CN111789837A (zh) * | 2020-08-31 | 2020-10-20 | 山东黄海科技创新研究院有限责任公司 | 用于预防和治疗幽门螺杆菌轻、中度感染的组合物 |
KR20210056279A (ko) * | 2019-11-08 | 2021-05-18 | 주식회사 홍도담 | 개복숭아 추출액을 포함하는 건강 기능성 식음료 조성물, 이를 포함하는 건강 기능성 식음료 및 이의 제조 방법 |
CN113912527A (zh) * | 2021-10-12 | 2022-01-11 | 自然资源部第三海洋研究所 | 一种采用疏水性低共熔溶剂提取虾青素的方法 |
-
2022
- 2022-04-07 CN CN202210362164.3A patent/CN114732130B/zh active Active
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1248912A (zh) * | 1997-02-27 | 2000-03-29 | 阿斯塔卡罗坦尼有限公司 | 用于预防和治疗螺杆菌属感染的口服制剂 |
FR2768335A1 (fr) * | 1997-09-12 | 1999-03-19 | Sederma Sa | Compositions a usage cosmetique ou dermopharmaceutique contenant une association d'extrait d'algue et d'exopolysaccharide |
CN103232375A (zh) * | 2013-04-03 | 2013-08-07 | 大连医诺生物有限公司 | 雨生红球藻中虾青素的高效提取新工艺 |
KR20140125506A (ko) * | 2013-04-19 | 2014-10-29 | 한국에너지기술연구원 | 헤마토코커스 플루비알리스로부터 아스타잔틴과 지질의 동시 생산방법 |
KR20180118951A (ko) * | 2017-04-24 | 2018-11-01 | 주식회사 메디비젼 | 안구 질환 예방 또는 개선용 건강기능식품 조성물 |
CN107173807A (zh) * | 2017-06-13 | 2017-09-19 | 烟台燕园科玛健康产业有限公司 | 一种含藻类提取物的抗氧化保健营养组合物 |
DE202018105422U1 (de) * | 2018-06-21 | 2018-10-19 | U.S. Nutraceuticals, Llc D/B/A Valensa International | Zusammensetzung zur Linderung von Gelenkschmerzen unter Verwendung von Hyaluronsäure und Eierschalenmembrankomponenten |
US20200289433A1 (en) * | 2019-03-14 | 2020-09-17 | Bioptik Technology, Inc. | Astaxanthin compound composition and the method thereof |
CN110115374A (zh) * | 2019-05-06 | 2019-08-13 | 云南爱尔康生物技术有限公司 | 一种增强免疫的雨生红球藻褐藻多糖精片及其制备方法 |
KR20210056279A (ko) * | 2019-11-08 | 2021-05-18 | 주식회사 홍도담 | 개복숭아 추출액을 포함하는 건강 기능성 식음료 조성물, 이를 포함하는 건강 기능성 식음료 및 이의 제조 방법 |
CN111789837A (zh) * | 2020-08-31 | 2020-10-20 | 山东黄海科技创新研究院有限责任公司 | 用于预防和治疗幽门螺杆菌轻、中度感染的组合物 |
CN113912527A (zh) * | 2021-10-12 | 2022-01-11 | 自然资源部第三海洋研究所 | 一种采用疏水性低共熔溶剂提取虾青素的方法 |
Non-Patent Citations (2)
Title |
---|
X WANG ET AL.: "Astaxanthin-rich algal meal and vitamin C inhibit Helicobacter pylori infection in BALB/cA mice", 《ANTIMICROBIAL AGENTS AND CHEMOTHERAPY》, vol. 44, no. 9, pages 2452 - 2457, XP008039976, DOI: 10.1128/AAC.44.9.2452-2457.2000 * |
张苗;刘晓娟;刘欣;: "超声辅助提取雨生红球藻渣多糖工艺优化", 食品工业科技, no. 20, pages 254 - 257 * |
Also Published As
Publication number | Publication date |
---|---|
CN114732130B (zh) | 2024-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Simayi et al. | Isolation, structural characterization, biological activity, and application of Glycyrrhiza polysaccharides: Systematic review | |
Kafle et al. | A review on medicinal properties of Psidium guajava | |
CN109846940A (zh) | 一种黄精多糖提取物及其提取方法和用途 | |
CN106420484A (zh) | 一种安肌舒敏精华液 | |
CN102293997B (zh) | 一种干姜提取物的制备方法 | |
CN113480676B (zh) | 低聚半乳糖醛酸多糖、复合物及其制备方法和应用 | |
CN103356691A (zh) | 以蕨麻为原料制备蕨麻粗多糖的方法及用途 | |
CN103977021A (zh) | 低聚古罗糖醛酸盐在制备防治肝损伤和各种肝炎、肝纤维化或肝硬化药物中的应用 | |
CN112535239B (zh) | 一种用于禽畜日常保健促生长的复方中草药饲料添加剂及其制备及应用 | |
CN107184702B (zh) | 一种防治家禽腺胃炎肌胃炎的中药组合物及其制备方法 | |
CN104672050A (zh) | 一种温郁金有效成分的综合提取方法 | |
CN114732130B (zh) | 含雨生红球藻且抑制胃粘膜受损的组合物及其应用 | |
CN104004110B (zh) | 一种从瓜子金中提取的瓜子金多糖及其应用 | |
CN107114781A (zh) | 一种用于保肝的保健食品及其制备方法 | |
KR102659842B1 (ko) | 차전자피 및 복합추출물을 포함하는 장 기능 개선 및 배변 촉진용 건강기능식품 조성물 및 이의 제조방법 | |
CN104926958A (zh) | 从泽兰中提取泽兰多糖的方法及其应用 | |
KR101230573B1 (ko) | 천년초 추출물 또는 백년초 추출물을 함유하는 천연 유화제 및 이를 포함하는 화장품 조성물, 식품 조성물 및 의약 조성물 | |
CN102618420A (zh) | 一种养生保健酒以及制作方法 | |
Mascolo et al. | Healing powers of aloes | |
KR101375347B1 (ko) | 홍삼약초 음료의 제조방법 및 상기 방법으로 제조된 홍삼 음료 | |
CN114365844A (zh) | 一种调节肠道菌群、提高肠道免疫的竹荪复方保健食品及其制备方法 | |
CN108969580B (zh) | 蓝布正总鞣质的制备方法及应用 | |
CN106520858B (zh) | 一种银杏叶水溶性膳食纤维的提取方法 | |
KR101835661B1 (ko) | 세리포리아락세라타 추출물을 함유하는 피부가려움 완화와 피부염 예방 기능의 화장료 조성물 및 이를 포함하는 화장품 | |
CN109528857A (zh) | 一种用于治疗雾霾引起的呼吸***疾病的桔梗颗粒及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |